دورية أكاديمية
أعرض في EDS

A novel antibacterial approach of Cecropin-B peptide loaded on chitosan nanoparticles against MDR Klebsiella pneumoniae isolates.

التفاصيل البيبلوغرافية
العنوان: A novel antibacterial approach of Cecropin-B peptide loaded on chitosan nanoparticles against MDR Klebsiella pneumoniae isolates.
المؤلفون: Okasha H; Biochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, Egypt. hend.oaa@gmail.com., Dahroug H; Microbiology Department, Theodor Bilharz Research Institute, Giza, Egypt., Gouda AE; Biochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, Egypt., Shemis MA; Biochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, Egypt.
المصدر: Amino acids [Amino Acids] 2023 Dec; Vol. 55 (12), pp. 1965-1980. Date of Electronic Publication: 2023 Nov 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Austria NLM ID: 9200312 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1438-2199 (Electronic) Linking ISSN: 09394451 NLM ISO Abbreviation: Amino Acids Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Wien ; New York : Springer-Verlag, c1991-
مواضيع طبية MeSH: Chitosan*/pharmacology , Chitosan*/therapeutic use , Cecropins*/pharmacology , Klebsiella Infections*/drug therapy , Klebsiella Infections*/microbiology , Nanoparticles*, Humans ; Klebsiella pneumoniae ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Porins/genetics ; Porins/pharmacology ; Porins/therapeutic use ; Microbial Sensitivity Tests
مستخلص: Egypt has witnessed the emergence of multidrug-resistant (MDR) Klebsiella pneumoniae, which has posed a serious healthcare challenge. The proper treatment choice for MDR-KP infections is not well determined which renders the problem more complicated, thus making the control of such infections a serious challenge for healthcare professionals. This study aims to encapsulate the cationic antimicrobial peptide; Cecropin-B (Cec-B), to increase its lifetime, drug targeting, and efficacy and study the antimicrobial effect of free and encapsulated recombinant rCec-B peptide on multidrug-resistant K. pneumoniae (MDR-KP) isolates. Fifty isolates were collected from different clinical departments at Theodore Bilharz Research Institute. Minimal inhibitory concentrations (MICs) of rCec-B against MDR-KP isolates were determined by the broth microdilution test. In addition, encapsulation of rCec-B peptide into chitosan nanoparticles and studying its bactericidal effect against MDR-KP isolates were also performed. The relative expression of efflux pump and porin coding genes (ArcrB, TolC, mtdK, and Ompk35) was detected by quantitative PCR in treated MDR-KP bacterial isolates compared to untreated isolates. Out of 60 clinical MDR isolates, 50 were MDR-KP. 60% of the isolates were XDR while 40% were MDR. rCec-B were bactericidal on 21 isolates, then these isolates were subjected to treatment using free nanocapsule in addition to the encapsulated peptide. Free capsules showed a mild cytotoxic effect on MDR-KP at the highest concentration. MIC of encapsulated rCec-B was higher than the free peptide. The expression level of genes encoding efflux and porin (ArcrB, TolC, mtdK, and Ompk35) was downregulated after treatment with encapsulated rCec-B. These findings indicate that encapsulated rCec-B is a promising candidate with potent antibacterial activities against drug-resistant K. pneumoniae.
(© 2023. The Author(s).)
References: FEMS Microbiol Rev. 2017 May 1;41(3):302-322. (PMID: 28419240)
Front Microbiol. 2021 Apr 16;12:604031. (PMID: 33935984)
Int J Mol Sci. 2022 Dec 14;23(24):. (PMID: 36555539)
AAPS PharmSciTech. 2006 Jun 02;7(2):E50. (PMID: 16796367)
Biochim Biophys Acta. 1990 Aug 17;1035(2):214-7. (PMID: 2393670)
Scientifica (Cairo). 2020 Jun 26;2020:3526286. (PMID: 32676212)
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. (PMID: 31494252)
Int J Pharm. 2003 Jan 2;250(1):215-26. (PMID: 12480287)
Iran J Pharm Res. 2012 Spring;11(2):481-93. (PMID: 24250471)
Front Microbiol. 2015 Apr 28;6:372. (PMID: 25972852)
Biotechnol Adv. 2020 Jul - Aug;41:107549. (PMID: 32302653)
Int J Infect Dis. 2016 Feb;43:17-20. (PMID: 26686939)
Heliyon. 2021 Dec 24;8(1):e08674. (PMID: 35028457)
Evol Bioinform Online. 2020 Jun 26;16:1176934320936266. (PMID: 32636607)
Int J Environ Res Public Health. 2019 Feb 19;16(4):. (PMID: 30791374)
Carbohydr Polym. 2017 Nov 1;175:170-177. (PMID: 28917853)
Am J Transl Res. 2019 Jul 15;11(7):3919-3931. (PMID: 31396309)
Poult Sci. 2013 Jun;92(6):1552-9. (PMID: 23687151)
Nat Commun. 2021 Jul 7;12(1):4188. (PMID: 34234121)
J Bacteriol. 2016 Nov 4;198(23):3200-3208. (PMID: 27645385)
Antibiotics (Basel). 2022 Sep 08;11(9):. (PMID: 36139997)
Saudi Pharm J. 2016 Jul;24(4):413-28. (PMID: 27330372)
Front Microbiol. 2020 Jun 19;11:1375. (PMID: 32636828)
Clin Microbiol Infect. 2012 Mar;18(3):268-81. (PMID: 21793988)
Biochim Biophys Acta Biomembr. 2020 Apr 1;1862(4):183177. (PMID: 31954105)
Microb Drug Resist. 2021 Feb;27(2):247-257. (PMID: 32635796)
Food Chem. 2019 Jan 15;271:614-622. (PMID: 30236723)
J Clin Microbiol. 2020 Feb 24;58(3):. (PMID: 31915289)
ACS Infect Dis. 2019 Jul 12;5(7):1200-1213. (PMID: 31045339)
Front Chem. 2021 Jun 18;9:691532. (PMID: 34222199)
BMC Microbiol. 2019 Mar 8;19(1):54. (PMID: 30849936)
Pharmaceutics. 2021 Jul 21;13(8):. (PMID: 34452072)
Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60. (PMID: 21859938)
Molecules. 2019 Jul 19;24(14):. (PMID: 31330957)
J Control Release. 2004 Nov 5;100(1):5-28. (PMID: 15491807)
Bioorg Chem. 2021 Oct;115:105266. (PMID: 34449322)
Curr Pharm Biotechnol. 2021;22(9):1235-1245. (PMID: 33397234)
Methods Enzymol. 2014;541:95-103. (PMID: 24674065)
Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. (PMID: 31209048)
Nanomaterials (Basel). 2018 Oct 13;8(10):. (PMID: 30322127)
Saudi J Biol Sci. 2022 May;29(5):3097-3106. (PMID: 35360502)
Sci Rep. 2016 Dec 22;6:38929. (PMID: 28004732)
Elife. 2017 Mar 29;6:. (PMID: 28355133)
Eur J Clin Microbiol Infect Dis. 2021 Jul;40(7):1451-1460. (PMID: 33559021)
Arch Microbiol. 2021 Sep;203(7):4351-4359. (PMID: 34110479)
Front Microbiol. 2019 Jul 23;10:1669. (PMID: 31396186)
Materials (Basel). 2020 Apr 24;13(8):. (PMID: 32344606)
فهرسة مساهمة: Keywords: Antibacterial; Bactericidal; Cationic antimicrobial peptide; Cecropin; Chitosan; Egypt; Klebsiella pneumoniae; Multidrug-resistant; Nanocapsule; PCR
المشرفين على المادة: 9012-76-4 (Chitosan)
0 (Cecropins)
0 (Anti-Bacterial Agents)
0 (Porins)
تواريخ الأحداث: Date Created: 20231115 Date Completed: 20231218 Latest Revision: 20231218
رمز التحديث: 20231218
مُعرف محوري في PubMed: PMC10724327
DOI: 10.1007/s00726-023-03356-4
PMID: 37966500
قاعدة البيانات: MEDLINE
الوصف
تدمد:1438-2199
DOI:10.1007/s00726-023-03356-4